Journal of medical virology · 2020
Development of epitope-based peptide vaccine against novel coronavirus 2019 (SARS-COV-2): Immunoinformatics approach.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bhattacharya Manojit, Sharma Ashish R, Patra Prasanta, Ghosh Pratik, Sharma Garima, Patra Bidhan C, Lee Sang-Soo, Chakraborty Chiranjib
Аннотация
Recently, a novel coronavirus (SARS-COV-2) emerged which is responsible for the recent outbreak in Wuhan, China. Genetically, it is closely related to SARS-CoV and MERS-CoV. The situation is getting worse and worse, therefore, there is an urgent need for designing a suitable peptide vaccine component against the SARS-COV-2. Here, we characterized spike glycoprotein to obtain immunogenic epitopes. Next, we chose 13 Major Histocompatibility Complex-(MHC) I and 3 MHC-II epitopes, having antigenic properties. These epitopes are usually linked to specific linkers to build vaccine components and molecularly dock on toll-like receptor-5 to get binding affinity. Therefore, to provide a fast immunogenic profile of these epitopes, we performed immunoinformatics analysis so that the rapid development of the vaccine might bring this disastrous situation to the end earlier.
Предметные рубрики MeSH
Amino Acid SequenceBetacoronavirusBinding SitesCOVID-19COVID-19 VaccinesComputational BiologyCoronavirus InfectionsEpitopesEpitopes, B-LymphocyteEpitopes, T-LymphocyteHistocompatibility Antigens Class IHistocompatibility Antigens Class IIHumansMiddle East Respiratory Syndrome CoronavirusMolecular Docking SimulationPandemicsPneumonia, ViralProtein BindingProtein Interaction Domains and MotifsProtein Structure, TertiarySevere acute respiratory syndrome-related coronavirusSARS-CoV-2Spike Glycoprotein, CoronavirusToll-Like Receptor 5Vaccines, SubunitViral Vaccines